Organogenesis (NASDAQ:ORGO) Posts Earnings Results, Beats Estimates By $0.11 EPS

Organogenesis (NASDAQ:ORGO) issued its quarterly earnings results on Thursday. The company reported $0.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.11, Zacks reports. The firm had revenue of $150.86 million for the quarter, compared to analysts’ expectations of $134.10 million. Organogenesis had a positive return on equity of 4.05% and a negative net margin of 1.30%. Organogenesis updated its FY 2025 guidance to EPS.

Organogenesis Trading Up 44.7%

NASDAQ:ORGO traded up $1.74 on Friday, hitting $5.63. 32,983,255 shares of the stock were exchanged, compared to its average volume of 722,316. The stock has a fifty day moving average of $4.43 and a 200-day moving average of $4.19. The stock has a market cap of $714.22 million, a PE ratio of -46.92 and a beta of 1.68. Organogenesis has a fifty-two week low of $2.61 and a fifty-two week high of $6.71.

Wall Street Analyst Weigh In

A number of analysts recently commented on ORGO shares. Wall Street Zen upgraded Organogenesis from a “hold” rating to a “strong-buy” rating in a research report on Saturday. Cantor Fitzgerald raised their price target on shares of Organogenesis from $7.00 to $9.00 and gave the stock an “overweight” rating in a research note on Friday, August 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Organogenesis in a report on Wednesday, October 8th. Finally, BTIG Research reissued a “buy” rating and issued a $7.00 price objective on shares of Organogenesis in a research report on Friday, September 26th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Organogenesis currently has a consensus rating of “Hold” and an average price target of $7.33.

Institutional Trading of Organogenesis

Institutional investors have recently added to or reduced their stakes in the business. First Light Asset Management LLC acquired a new position in Organogenesis in the second quarter worth $24,804,000. Raymond James Financial Inc. raised its holdings in shares of Organogenesis by 5.7% during the second quarter. Raymond James Financial Inc. now owns 444,240 shares of the company’s stock worth $1,626,000 after purchasing an additional 23,919 shares during the period. Russell Investments Group Ltd. lifted its position in shares of Organogenesis by 36.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 168,152 shares of the company’s stock worth $617,000 after buying an additional 45,021 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of Organogenesis by 25.6% in the 2nd quarter. American Century Companies Inc. now owns 164,793 shares of the company’s stock valued at $603,000 after buying an additional 33,573 shares during the period. Finally, Mink Brook Asset Management LLC bought a new stake in shares of Organogenesis during the 2nd quarter valued at about $340,000. 49.57% of the stock is owned by hedge funds and other institutional investors.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.